Microba Life Sciences (ASX:MAP) Tax Expense: A$-0.22 Mil (TTM As of Dec. 2025)


What is Microba Life Sciences Tax Expense?

Microba Life Sciences ASX:MAP -5.00% Tax Expense is A$-0.22 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Microba Life Sciences's tax expense for the months ended in Dec. 2025 was A$-0.25 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.22 Mil.


Microba Life Sciences  (ASX:MAP) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Microba Life Sciences Tax Expense Related Terms


Microba Life Sciences Tax Expense Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Tax Expense Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Tax Expense
0.01 0.01 -0.05 -0.11

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only -0.02 -0.03 -0.14 0.03 -0.25

Microba Life Sciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of A$-0.22 Mil mean?
Microba Life Sciences (ASX:MAP) has a Tax Expense of A$-0.22 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' Tax Expense too high?
Microba Life Sciences' current Tax Expense is A$-0.22 Mil.
How does Microba Life Sciences' Tax Expense compare to TMO and DHR?
Microba Life Sciences' Tax Expense of A$-0.22 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Medical Diagnostics & Research company?
A good Tax Expense depends on the Medical Diagnostics & Research industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Tax Expense is A$-0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.8% below its estimated fair value. The current Tax Expense is A$-0.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Tax Expense is A$-0.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.